EpiEndo Pharmaceuticals ehf

Their core work

EpiEndo Pharmaceuticals is an Icelandic biopharmaceutical SME focused on developing first-in-class drugs that target the epithelial barrier in chronic airway diseases. Their core scientific premise is that restoring or enhancing the integrity of the airway epithelium — the lining that separates the lung tissue from inhaled pathogens and irritants — can modify disease progression rather than merely managing symptoms. They have advanced a drug candidate from early feasibility (Bronchomycn) through to a full Phase 2-scale EU-funded development program (BRONCHOTHELIN), suggesting a pipeline in active clinical or preclinical development. Their work sits at the intersection of pulmonology, epithelial biology, and drug development, addressing conditions such as asthma, COPD, and other chronic obstructive or inflammatory airway disorders.

What they specialise in

How they've shifted over time

EpiEndo's H2020 trajectory follows a textbook SME Instrument progression: a 2017 feasibility study (Bronchomycn, €50k) to validate the scientific and commercial case, followed by a 2020 full development grant (BRONCHOTHELIN, €2.5M) to advance the drug candidate toward market. The thematic focus has not shifted — both projects address epithelial barrier dysfunction in airway disease — but the scale, ambition, and development maturity have increased substantially. This is not diversification; it is deepening commitment to a single, well-defined therapeutic hypothesis.

EpiEndo is on a focused, single-asset development trajectory toward clinical-stage respiratory drug candidacy, making them a potential target for pharma licensing, co-development, or acquisition rather than broad consortium partnership.

How they like to work

EpiEndo has acted exclusively as project coordinator in both of their H2020 projects, consistent with the SME Instrument format where SMEs lead their own innovation projects without requiring a traditional multi-partner consortium. No external consortium partners are recorded, which is expected for SME Instrument Phase 1 and Phase 2 grants — these are company-driven, not network-driven. Working with EpiEndo would likely mean engaging them as a technology originator or licensing partner rather than as a consortium member in a larger collaborative project.

EpiEndo has no recorded H2020 consortium partners, which reflects the solo-company nature of the SME Instrument funding scheme they used. Their collaborative network is not visible through CORDIS data and would need to be assessed through their clinical trial registrations, academic publications, or CRO partnerships.

What sets them apart

EpiEndo occupies a rare niche: a small Icelandic pharma company with a coherent, mechanistically grounded thesis around epithelial barrier restoration as a disease-modifying strategy for airway conditions — a space dominated by symptom management. Their successful progression from SME Phase 1 to Phase 2 signals that their concept passed competitive EU scientific review twice, lending external validation to their pipeline. For partners or investors in respiratory medicine, they represent a differentiated asset with an identifiable mechanism of action, not a generic drug reformulation play.

Highlights from their portfolio

• BRONCHOTHELIN
  The company's lead programme: a €2.5M EU-backed development grant for a first-in-class disease-modifying drug for chronic airway disorders, representing one of the largest single SME Instrument Phase 2 awards and confirming the scientific credibility of their epithelial barrier approach.
• Bronchomycn
  The Phase 1 feasibility study that launched the pipeline, demonstrating the company's ability to articulate a commercially viable epithelial barrier concept convincingly enough to secure follow-on Phase 2 funding.